Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNYNF crawled date : 2022 - 05 - 20 save search
Rack Up Another Win for Dupixent, This One as First Treatment for EoE
Published: 2022-05-20 (Crawled : 21:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 10.05%
H: 0.07%
C: 0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
treatment one
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Published: 2022-05-20 (Crawled : 20:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
dupixent treatment fda children order
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
Published: 2022-05-20 (Crawled : 20:00) - globenewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
dupixent treatment fda children order
BioSpace Movers & Shakers: Jeffrey Leiden, Don Hayden, Zentalis, Entera and More
Published: 2022-05-20 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 10.05%
H: 0.07%
C: 0.07%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.37%
H: 0.28%
C: -0.14%
VCYT | $19.43 1.2% 1.18% 1.4M
|
Health Technology
|
| O: 9.3%
H: 3.13%
C: 2.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 4.39%
H: 1.34%
C: 1.15%
ACIU | $2.375 -0.21% -0.21% 320K
|
Health Technology
|
| O: 4.68%
H: 2.56%
C: 0.64%
ASLAN, Kymera Target Atopic Dermatitis at Dermatology Meeting
Published: 2022-05-20 (Crawled : 13:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 10.05%
H: 0.07%
C: 0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
dermatitis
BioSpace Movers & Shakers, May 20
Published: 2022-05-20 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 10.05%
H: 0.07%
C: 0.07%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.37%
H: 0.28%
C: -0.14%
VCYT | $19.43 1.2% 1.18% 1.4M
|
Health Technology
|
| O: 9.3%
H: 3.13%
C: 2.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 4.39%
H: 1.34%
C: 1.15%
ACIU | $2.375 -0.21% -0.21% 320K
|
Health Technology
|
| O: 4.68%
H: 2.56%
C: 0.64%
BioSpace Movers & Shakers: Jeffrey Leiden, Don Hayden, Zentalis, Entera and M...
Published: 2022-05-20 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 10.05%
H: 0.07%
C: 0.07%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.37%
H: 0.28%
C: -0.14%
VCYT | $19.43 1.2% 1.18% 1.4M
|
Health Technology
|
| O: 9.3%
H: 3.13%
C: 2.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 4.39%
H: 1.34%
C: 1.15%
ACIU | $2.375 -0.21% -0.21% 320K
|
Health Technology
|
| O: 4.68%
H: 2.56%
C: 0.64%
Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
Published: 2022-05-20 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 10.05%
H: 0.07%
C: 0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.5%
H: 0.0%
C: 0.0%
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: -2.71%
H: 2.3%
C: -3.02%
kt-474 preclinical skin therapeutics pre-clinical
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.